Open AccessAlopecia areata following pembrolizumab: A case report and literature review
Author(s) -
Hara Reiko,
Sawada Yu
Publication year - 2022
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12236
Subject(s) - alopecia areata , pembrolizumab , medicine , immune system , hair loss , immunology , immune checkpoint , immunotherapy , dermatology
Since malignancies develop their escape strategy from anti‐tumor immunity mediated by PD‐1/PD‐L1 or CTLA‐4, the recent advancement of immune checkpoint inhibitor treatment proves the importance of immune reaction against malignancies. On the other hand, healthy human tissue or organs also need to tolerance mechanism escaping from immune reactions not to cause excessive inflammatory reactions. We report a case of alopecia areata following pembrolizumab administration and also review the previously published cases of alopecia areata following PD‐1/PD‐L1 targeted therapy further.